Top

Current Allergy and Asthma Reports

Published in:

12-05-2023 | Aneurysm

Multisystem Inflammatory Syndrome in Children and Kawasaki Disease: Parallels in Pathogenesis and Treatment

Authors: Laura Cannon, M. Jay Campbell, Eveline Y. Wu

Published in: Current Allergy and Asthma Reports | Issue 6/2023

Abstract

Purpose of Review

Since it first appeared, multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) has been compared to Kawasaki disease (KD). Although there were early parallels between MIS-C and KD, key differences emerged over time. Here, we aim to compare the pathogenesis, clinical presentation, treatment, and outcomes of MIS-C and KD.

Recent Findings

In this article, we review and compare MIS-C and KD, highlighting differentiating features. We discuss the epidemiological and immunological factors along with clinical and laboratory features which discern MIS-C from KD. We also compare treatment and our understanding of long-term outcomes.

Summary

Though parallels exist between MIS-C and KD, distinguishing the two is important for clinical management of patients, counseling about natural history, and determining long-term monitoring. While both MIS-C and KD are characterized by profound inflammation and inflammatory vasculopathy, further study is needed to determine whether they are distinct immunopathogenic disorders.

Kawasaki T. Kawasaki disease. Int J Rheum Dis. 2014;17(5):597–600. https://doi.org/10.1111/1756-185x.12408.CrossRefPubMed

Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607–8. https://doi.org/10.1016/s0140-6736(20)31094-1.CrossRefPubMedPubMedCentral

Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157–60. https://doi.org/10.23750/abm.v91i1.9397.

Lo MS. A framework for understanding Kawasaki disease pathogenesis. Clin Immunol. 2020;214:108385. https://doi.org/10.1016/j.clim.2020.108385.

Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40(1):35–42. https://doi.org/10.1038/ng.2007.59.CrossRefPubMed

Armaroli G, Verweyen E, Pretzer C, Kessel K, Hirono K, Ichida F, et al. Monocyte-derived interleukin-1β as the driver of S100A12-induced sterile inflammatory activation of human coronary artery endothelial cells: implications for the pathogenesis of Kawasaki disease. Arthritis Rheumatol. 2019;71(5):792–804. https://doi.org/10.1002/art.40784.CrossRefPubMed

Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin Exp Immunol. 2010;162(1):131–7. https://doi.org/10.1111/j.1365-2249.2010.04236.x.CrossRefPubMedPubMedCentral

Noval Rivas M, Lee Y, Wakita D, Chiba N, Dagvadorj J, Shimada K, et al. CD8+ T cells contribute to the development of coronary arteritis in the Lactobacillus casei cell wall extract-induced murine model of Kawasaki disease. Arthritis Rheumatol. 2017;69(2):410–21. https://doi.org/10.1002/art.39939.CrossRefPubMed

Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol. 2010;22(5):551–60. https://doi.org/10.1097/BOR.0b013e32833cf051.CrossRefPubMed

10.

Doi M, Takeda T, Sakurai Y, Kato J, Hayashi T, Fukuda K, et al. Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease. J Investig Allergol Clin Immunol. 2010;20(5):413–8.

11.

Rowley AH, Eckerley CA, Jäck HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol. 1997;159(12):5946–55.CrossRefPubMed

12.

Noval Rivas M, Wakita D, Franklin MK, Carvalho TT, Abolhesn A, Gomez AC, et al. Intestinal permeability and IgA provoke immune vasculitis linked to cardiovascular inflammation. Immunity. 2019;51(3):508-21.e6. https://doi.org/10.1016/j.immuni.2019.05.021.CrossRefPubMed

13.

Chua PK, Melish ME, Yu Q, Yanagihara R, Yamamoto KS, Nerurkar VR. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Clin Diagn Lab Immunol. 2003;10(2):308–14. https://doi.org/10.1128/cdli.10.2.308-314.2003.CrossRefPubMedPubMedCentral

14.

Santos-Rebouças CB, Piergiorge RM, Dos Santos FC, SeixasZeitel R, Gerber AL, Rodrigues MCF, et al. Host genetic susceptibility underlying SARS-CoV-2-associated multisystem inflammatory syndrome in Brazilian children. Mol Med. 2022;28(1):153. https://doi.org/10.1186/s10020-022-00583-5.CrossRefPubMedPubMedCentral

15.

Abolhassani H, Delavari S, Landegren N, Shokri S, Bastard P, Du L, et al. Genetic and immunologic evaluation of children with inborn errors of immunity and severe or critical COVID-19. J Allergy Clin Immunol. 2022;150(5):1059–73. https://doi.org/10.1016/j.jaci.2022.09.005.CrossRefPubMedPubMedCentral

16.

• Chou J, Platt CD, Habiballah S, Nguyen AA, Elkins M, Weeks S, et al. Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C). J Allergy Clin Immunol. 2021;148(3):732–8.e1. https://doi.org/10.1016/j.jaci.2021.06.024. A single-center cohort study demonstrating MIS-C patients were enriched for monogenic susceptibility to inflammation.

17.

Lee PY, Platt CD, Weeks S, Grace RF, Maher G, Gauthier K, et al. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immunol. 2020;146(5):1194-200.e1. https://doi.org/10.1016/j.jaci.2020.07.033.CrossRefPubMedPubMedCentral

18.

Carter MJ, Fish M, Jennings A, Doores KJ, Wellman P, Seow J, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nat Med. 2020;26(11):1701–7. https://doi.org/10.1038/s41591-020-1054-6.CrossRefPubMed

19.

Diorio C, Henrickson SE, Vella LA, McNerney KO, Chase J, Burudpakdee C, et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest. 2020;130(11):5967–75. https://doi.org/10.1172/jci140970.CrossRefPubMedPubMedCentral

20.

Diorio C, McNerney KO, Lambert M, Paessler M, Anderson EM, Henrickson SE, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020;4(23):6051–63. https://doi.org/10.1182/bloodadvances.2020003471.CrossRefPubMedPubMedCentral

21.

Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell. 2020;183(4):982-95.e14. https://doi.org/10.1016/j.cell.2020.09.034.CrossRefPubMedPubMedCentral

22.

Sharma C, Ganigara M, Galeotti C, Burns J, Berganza FM, Hayes DA, et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat Rev Rheumatol. 2021;17(12):731–48. https://doi.org/10.1038/s41584-021-00709-9.CrossRefPubMedPubMedCentral

23.

Vella LA, Giles JR, Baxter AE, Oldridge DA, Diorio C, Kuri-Cervantes L, et al. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. Sci Immunol. 2021;6(57). https://doi.org/10.1126/sciimmunol.abf7570.

24.

Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell. 2020;183(4):968-81.e7. https://doi.org/10.1016/j.cell.2020.09.016.CrossRefPubMedPubMedCentral

25.

• Esteve-Sole A, Anton J, Pino-Ramirez RM, Sanchez-Manubens J, Fumadó V, Fortuny C, et al. Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease. J Clin Invest. 2021;131(6). https://doi.org/10.1172/jci144554. The study performed cytokine profiling in pediatric patients with MIS-C and pre-pandemic KD, and results suggest IFN-γ and inflammatory monocytes are important drivers of inflammation in MIS-C.

26.

Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, Schonberger LB. Hospitalizations for Kawasaki syndrome among children in the United States, 1997–2007. Pediatr Infect Dis J. 2010;29(6):483–8. https://doi.org/10.1097/INF.0b013e3181cf8705.CrossRefPubMed

27.

Son MB, Gauvreau K, Ma L, Baker AL, Sundel RP, Fulton DR, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009;124(1):1–8. https://doi.org/10.1542/peds.2008-0730.CrossRefPubMed

28.

Sundel RP. Kawasaki disease. Rheum Dis Clin North Am. 2015;41(1):63–73, viii. https://doi.org/10.1016/j.rdc.2014.09.010.

29.

• Son MBF, Gauvreau K, Tremoulet AH, Lo M, Baker AL, de Ferranti S, et al. Risk model development and validation for prediction of coronary artery aneurysms in Kawasaki disease in a North American population. J Am Heart Assoc. 2019;8(11):e011319. https://doi.org/10.1161/jaha.118.011319. This study aims to develop a risk model predictive of coronary artery aneurysm development, a major determinant of Kawasaki disease morbidity, for North American cohorts.

30.

Salgado AP, Ashouri N, Berry EK, Sun X, Jain S, Burns JC, et al. High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease. J Pediatr. 2017;185:112-6.e1. https://doi.org/10.1016/j.jpeds.2017.03.025.CrossRefPubMedPubMedCentral

31.

Gámez-González LB, Murata C, Muñoz-Ramírez M, Yamazaki-Nakashimada M. Clinical manifestations associated with Kawasaki disease shock syndrome in Mexican children. Eur J Pediatr. 2013;172(3):337–42. https://doi.org/10.1007/s00431-012-1879-1.CrossRefPubMed

32.

Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347–58. https://doi.org/10.1056/NEJMoa2021756.CrossRefPubMed

33.

Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334–46. https://doi.org/10.1056/NEJMoa2021680.

34.

Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324(3):259–69. https://doi.org/10.1001/jama.2020.10369.CrossRefPubMedPubMedCentral

35.

•• Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19. JAMA. 2021;325(11):1074–87. https://doi.org/10.1001/jama.2021.2091. This report is one of the largest case series including 539 children with MIS-C from the Overcoming COVID-19 surveillance registry. The study observed that most cardiovascular involvement resolved over time.

36.

Susarla SC, Fan LL. Diffuse alveolar hemorrhage syndromes in children. Curr Opin Pediatr. 2007;19(3):314–20. https://doi.org/10.1097/MOP.0b013e3280dd8c4a.CrossRefPubMed

37.

Son MBF, Burns JC, Newburger JW. A new definition for multisystem inflammatory syndrome in children. Pediatr. 2023. https://doi.org/10.1542/peds.2022-060302.

38.

Miller J, Cantor A, Zachariah P, Ahn D, Martinez M, Margolis KG. Gastrointestinal symptoms as a major presentation component of a novel multisystem inflammatory syndrome in children that is related to Coronavirus disease 2019: a single center experience of 44 cases. Gastroenterology. 2020;159(4):1571-4.e2. https://doi.org/10.1053/j.gastro.2020.05.079.CrossRefPubMed

39.

Baker AL, Lu M, Minich LL, Atz AM, Klein GL, Korsin R, et al. Associated symptoms in the ten days before diagnosis of Kawasaki disease. J Pediatr. 2009;154(4):592-5.e2. https://doi.org/10.1016/j.jpeds.2008.10.006.CrossRefPubMed

40.

McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–99. https://doi.org/10.1161/cir.0000000000000484.CrossRefPubMed

41.

Wu EY, Campbell MJ. Cardiac Manifestations of multisystem inflammatory syndrome in children (MIS-C) following COVID-19. Curr Cardiol Rep. 2021;23(11):168. https://doi.org/10.1007/s11886-021-01602-3.CrossRefPubMedPubMedCentral

42.

•• Son MBF, Murray N, Friedman K, Young CC, Newhams MM, Feldstein LR, et al. Multisystem inflammatory syndrome in children - initial therapy and outcomes. N Engl J Med. 2021;385(1):23–34. https://doi.org/10.1056/NEJMoa2102605. This study looked at 518 MIS-C patients from the Overcoming COVID-19 surveillance registry and found that initial treatment with IVIG plus corticosteroids was associated with lower risk of cardiovascular dysfunction than IVIG alone.

43.

Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017;1(1):Cd011188. https://doi.org/10.1002/14651858.CD011188.pub2.

44.

Son MBF, Gauvreau K, Kim S, Tang A, Dedeoglu F, Fulton DR, et al. Predicting coronary artery aneurysms in Kawasaki disease at a North American Center: an assessment of baseline z scores. J Am Heart Assoc. 2017;6(6). https://doi.org/10.1161/jaha.116.005378.

45.

• de Graeff N, Groot N, Ozen S, Eleftheriou D, Avcin T, Bader-Meunier B, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative. Rheumatology (Oxford). 2019;58(4):672–82. https://doi.org/10.1093/rheumatology/key344. This report provides international evidence-based recommendations for diagnosing and treated KD in children to facilitate uniformity in care.

46.

Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613–20. https://doi.org/10.1016/s0140-6736(11)61930-2.CrossRefPubMed

47.

Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731–8. https://doi.org/10.1016/s0140-6736(13)62298-9.CrossRefPubMed

48.

Burns JC, Roberts SC, Tremoulet AH, He F, Printz BF, Ashouri N, et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health. 2021;5(12):852–61. https://doi.org/10.1016/s2352-4642(21)00270-4.CrossRefPubMed

49.

Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 1. Arthritis Rheumatol. 2020;72(11):1791–805. https://doi.org/10.1002/art.41454.CrossRefPubMedPubMedCentral

50.

Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 2. Arthritis Rheumatol. 2021;73(4):e13–29. https://doi.org/10.1002/art.41616.CrossRefPubMedPubMedCentral

51.

•• Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. Arthritis Rheumatol. 2022;74(4):e1-e20. https://doi.org/10.1002/art.42062. The most recent version of clinical guidance recommendations for MIS-C endorsed by the American College of Rheumatology.

52.

McArdle AJ, Vito O, Patel H, Seaby EG, Shah P, Wilson C, et al. Treatment of multisystem inflammatory syndrome in children. N Engl J Med. 2021;385(1):11–22. https://doi.org/10.1056/NEJMoa2102968.CrossRefPubMed

53.

Whitworth H, Sartain SE, Kumar R, Armstrong K, Ballester L, Betensky M, et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood. 2021;138(2):190–8. https://doi.org/10.1182/blood.2020010218.CrossRefPubMedPubMedCentral

54.

Zambrano LD, Newhams MM, Olson SM, Halasa NB, Price AM, Boom JA, et al. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12–18 years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71(2):52–8. https://doi.org/10.15585/mmwr.mm7102e1.

55.

Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736–54. https://doi.org/10.1161/circulationaha.106.183095.CrossRefPubMed

56.

Senzaki H. Long-term outcome of Kawasaki disease. Circulation. 2008;118(25):2763–72. https://doi.org/10.1161/circulationaha.107.749515.CrossRefPubMed

57.

Akagi T, Rose V, Benson LN, Newman A, Freedom RM. Outcome of coronary artery aneurysms after Kawasaki disease. J Pediatr. 1992;121(5 Pt 1):689–94. https://doi.org/10.1016/s0022-3476(05)81894-3.CrossRefPubMed

58.

Miller AD, Zambrano LD, Yousaf AR, Abrams JY, Meng L, Wu MJ, et al. Multisystem inflammatory syndrome in children-United States, February 2020-July 2021. Clin Infect Dis. 2022;75(1):e1165–75. https://doi.org/10.1093/cid/ciab1007.CrossRefPubMed

59.

Capone CA, Misra N, Ganigara M, Epstein S, Rajan S, Acharya SS, et al. Six month follow-up of patients with multi-system inflammatory syndrome in children. Pediatr. 2021;148(4). https://doi.org/10.1542/peds.2021-050973.

60.

Chakraborty A, Philip R, Santoso M, Naik R, Merlocco A, Johnson JN. Cardiovascular magnetic resonance in children with multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19: institutional protocol-based medium-term follow-up study. Pediatr Cardiol. 2022;43(8):1879–87. https://doi.org/10.1007/s00246-022-02927-8.CrossRefPubMedPubMedCentral

61.

Barris DM, Keelan J, Ahluwalia N, Jhaveri S, Cohen J, Stern K, et al. Midterm outcomes and cardiac magnetic resonance imaging following multisystem inflammatory syndrome in children. J Pediatr. 2022;241:237-41.e1. https://doi.org/10.1016/j.jpeds.2021.10.009.CrossRefPubMed

62.

Truong DT, Trachtenberg FL, Pearson GD, Dionne A, Elias MD, Friedman K, et al. The NHLBI study on long-term outcomes after the multisystem inflammatory syndrome in children (MUSIC): design and objectives. Am Heart J. 2022;243:43–53. https://doi.org/10.1016/j.ahj.2021.08.003.CrossRefPubMed

Title: Multisystem Inflammatory Syndrome in Children and Kawasaki Disease: Parallels in Pathogenesis and Treatment
Authors: Laura Cannon
M. Jay Campbell
Eveline Y. Wu
Publication date: 12-05-2023
Publisher: Springer US
Keywords: Aneurysm
Aneurysm
Kawasaki Disease
Kawasaki Disease
Kawasaki Disease
Published in: Current Allergy and Asthma Reports / Issue 6/2023
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI: https://doi.org/10.1007/s11882-023-01083-0

At a glance: The STEP trials

Springer Medicine

Multisystem Inflammatory Syndrome in Children and Kawasaki Disease: Parallels in Pathogenesis and Treatment

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 6/2023

Artificial Intelligence: Exploring the Future of Innovation in Allergy Immunology

The Role of Defensins as Pollen and Food Allergens

Lessons from Dairy Farmers for Occupational Allergy and Respiratory Disease

Effects of Tezepelumab on Quality of Life of Patients with Moderate-to-Severe, Uncontrolled Asthma: Systematic Review and Meta-Analysis

Nontraditional Occupational Exposures to Crude Oil Combustion Disasters and Respiratory Disease Risk: A Narrative Review of Literature

Mechanistic and Therapeutic Approaches to Occupational Exposure-Associated Allergic and Non-Allergic Asthmatic Disease